X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
IVA337 (lanifibranor) is an orally-available small molecule that acts by activating all three peroxisome proliferator activated receptor (PPAR) isoforms. It is being evaluated for the treatment of Nonalcoholic Steatohepatitis and Diabetes Mellitus, Type 2.
Lead Product(s): Lanifibranor,Empagliflozin
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: IVA337
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2024
Details:
IVA-337 (lanifibranor) is a pan-PPAR (peroxisome proliferator–activated receptor) agonist, which is being evaluated for the treatment of Nonalcoholic Steatohepatitis.
Lead Product(s): Lanifibranor
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: IVA337
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2024
Details:
Inventiva intends to use the proceeds to fund part of its ongoing pivotal NATiV3 Phase III clinical trial evaluating IVA-337 (lanifibranor), an orally-available small molecule, in patients with NASH.
Lead Product(s): Lanifibranor
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: IVA337
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: European Investment Bank
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing January 10, 2024
Details:
IVA337 (lanifibranor) is a PPAR agonist small molecule drug candidate, which is currently being evaluated for the treatment of non-alcoholic steatohepatitis.
Lead Product(s): Lanifibranor
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: IVA337
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2023
Details:
IVA337 (lanifibranor) is a pan-PPAR (peroxisome proliferator–activated receptor) agonist, which is being evaluated in phase 3 clinical trials for the treatment of Nonalcoholic Steatohepatitis.
Lead Product(s): Lanifibranor
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: IVA337
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 04, 2023
Details:
Under the agreement, Hepalys will develop and commercialize Inventiva’s proprietary drug candidate IVA337 (lanifibranor), an orally-available small molecule, PPAR agonist, for the treatment of non-alcoholic steatohepatitis (NASH) in Japan and South Korea.
Lead Product(s): Lanifibranor
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: IVA337
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hepalys Pharma
Deal Size: $241.0 million Upfront Cash: $10.0 million
Deal Type: Licensing Agreement September 20, 2023
Details:
The company will use the proceeds for the Phase III evaluation of IVA337 (lanifibranor), a pan-peroxisome proliferator-activated receptor agonist, in the treatment of patients suffering from NASH and for its other pre-clinical and clinical programs, in particular Yap-Tead.
Lead Product(s): Lanifibranor
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: IVA337
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Qatar Holding
Deal Size: $38.6 million Upfront Cash: Undisclosed
Deal Type: Financing August 31, 2023
Details:
IVA337 (lanifibranor), is an orally-available small molecule which induces anti-fibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three PPAR isoforms, regulating gene expression and evaluating in patients with T2D and NAFLD.
Lead Product(s): Lanifibranor
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: IVA337
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 13, 2023
Details:
IVA337 (Lanifibranor), is an orally-available small molecule which induces anti-fibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three PPAR isoforms, regulating gene expression.
Lead Product(s): Lanifibranor
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: IVA337
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sino Biopharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2023
Details:
IVA337 (Lanifibranor), is an orally-available small molecule which induces anti-fibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three PPAR isoforms, regulating gene expression.
Lead Product(s): Lanifibranor
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: IVA337
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
